ProPhase Labs, Inc. (NASDAQ:PRPH – Get Free Report) was the recipient of a large decrease in short interest in the month of February. As of February 28th, there was short interest totalling 1,660,000 shares, a decrease of 62.4% from the February 13th total of 4,420,000 shares. Based on an average daily volume of 8,860,000 shares, the days-to-cover ratio is currently 0.2 days. Currently, 8.8% of the shares of the company are short sold.
Analyst Upgrades and Downgrades
Separately, StockNews.com started coverage on ProPhase Labs in a research note on Tuesday, February 25th. They issued a “sell” rating for the company.
Check Out Our Latest Stock Report on ProPhase Labs
ProPhase Labs Stock Performance
Hedge Funds Weigh In On ProPhase Labs
Hedge funds and other institutional investors have recently bought and sold shares of the company. HighTower Advisors LLC boosted its holdings in shares of ProPhase Labs by 18.3% in the third quarter. HighTower Advisors LLC now owns 179,045 shares of the company’s stock valued at $434,000 after acquiring an additional 27,673 shares in the last quarter. Geode Capital Management LLC grew its holdings in ProPhase Labs by 9.2% during the third quarter. Geode Capital Management LLC now owns 160,735 shares of the company’s stock worth $389,000 after acquiring an additional 13,590 shares during the period. Sheets Smith Wealth Management purchased a new position in shares of ProPhase Labs in the 4th quarter valued at about $158,000. SVB Wealth LLC purchased a new position in ProPhase Labs in the fourth quarter valued at about $36,000. Finally, Perritt Capital Management Inc raised its holdings in ProPhase Labs by 129.1% during the fourth quarter. Perritt Capital Management Inc now owns 190,000 shares of the company’s stock worth $144,000 after purchasing an additional 107,068 shares during the last quarter. 9.45% of the stock is currently owned by hedge funds and other institutional investors.
ProPhase Labs Company Profile
ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
Read More
- Five stocks we like better than ProPhase Labs
- The How And Why of Investing in Oil Stocks
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Do ETFs Pay Dividends? What You Need to Know
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- 3 Warren Buffett Stocks to Buy Now
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.